Notable 52-Week Highs and Lows of the Day 02/25: (HTZ) (AMGN) (UAL) High; (AFFY) (DVAX) (CLSN) Low


FREE Breaking News Alerts from StreetInsider.com!

E-mail Address
February 25, 2013 1:52 PM EST Send to a Friend
Get Alerts HTZ Hot Sheet
Price: $25.39 -1.01%

Overall Analyst Rating:
    NEUTRAL (Up Up)

EPS Growth %: +320.0%
Trade HTZ Now!
This report is an intraday check of some of the more notable stocks that have hit a 52-week high or low so far today.

52-Week High:
  • Hertz Global Holdings (NYSE: HTZ) $20.35. Hertz higher after reporting Q4 results earlier. EPS of 33 cents and revs of $2.3 billion topped expectations calling for EPS of 31 cents and revs of $2.24 billion. For an updated outlook, click here.

  • Amgen Inc. (Nasdaq: AMGN) high of $91.25. Amgen issued comments an analysis by the Congressional Budget Office released this week. The company said that, contrary to the implications of past media reports, keeping oral-only drugs in Medicare Part D would actually achieve significant savings over time for both taxpayers and the Medicare program.

  • United Continental Holdings, Inc. (NYSE: UAL) high of $27.22. United Continental moving higher on analyst comments that consumer might be more open to rate hikes now than previously in 2013.

  • Gilead (Nasdaq: GILD) high of $43.35. Gilead boosted a little today as Bank of America/Merrill Lynch added the stock to its US 1 List. Shares were up as much as 2.1 percent on Monday's session.
52-Week Low:
  • Affymax, Inc. (Nasdaq: AFFY) low of $2.34. Affymax and Takeda Pharmaceutical Company Limited announced that they have decided to voluntarily recall all lots of OMONTYS Injection to the user level as a result of new postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which can be life-threatening or fatal. Shares fell 85.8 percent to the new low today. Analysts have largely taken the knife to Affymax, click here for more color.

  • Dynavax Technologies Corp. (Nasdaq: DVAX) low of $1.87. Dynavax reported that it received a Complete Response Letter (CRL) from the FDA regarding its Biologic License Application (BLA) for HEPLISAV, an investigational adult hepatitis B vaccine.

  • Frontline (NYSE: FRO) low of $2.10. Frontline still moving lower after reporting a narrower-than-expected Q4 loss of 21 cents per share last Friday, though guidance left something to be desired. For more color, click here.

  • Celsion Corp (Nasdaq: CLSN) low of $1.02. Investors still pricing in a $15 million at-the-market registered direct offering, which was announced last week.


Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here


You May Also Be Interested In


Related Categories

Special Reports

Related Entities

Merrill Lynch, Bank of America, Earnings

Add Your Comment